Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.2147/COPD.S154097 | ||||
| Año | 2018 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Conclusion: COPD management in specialist practice in Latin America does not follow the current guideline recommendations and there is an overuse of ICSs in patients with COPD from this region. Treatment regimens including the use of long-acting bronchodilators are associated with the highest adherence.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Casas, Alejandro | Hombre |
Univ Rosario - Colombia
Universidad del Rosario - Colombia |
| 2 | Montes De Oca, María | Mujer |
Univ Cent Venezuela - Venezuela
Universidad Central de Venezuela - Venezuela |
| 3 | Menezes, Ana M. B. | - |
Univ Fed Pelotas - Brasil
|
| 4 | Wehrmeister, Fernando C. | Hombre |
Univ Fed Pelotas - Brasil
Universidade Federal de Pelotas - Brasil |
| 5 | Lopez, M. V. | Mujer |
UNIV REPUBLICA - Uruguay
|
| 5 | Varela, Maria Victorina Lopez | Mujer |
Universidad La República - Uruguay
UNIV REPUBLICA - Uruguay Universidad de la República - Uruguay |
| 6 | MENDOZA-INSUNZA, LAURA | Mujer |
Hospital Clínico Universidad de Chile - Chile
Hospital Clínico de la Universidad de Chile - Chile Hosp Clin Univ Chile - Chile |
| 7 | Ramirez, Larissa | Mujer |
AstraZeneca - Costa Rica
AstraZeneca - Reino Unido |
| 8 | Miravitlles, M. | Hombre |
Hosp Univ Vall dHebron - España
Hospital Universitari Vall d'Hebron - España |
| 9 | LASSYC Team | Corporación |
| Agradecimiento |
|---|
| This observational study was funded by AstraZeneca Latin America. Editorial support was provided by Dr Ian Wright, Wright Medical Communications Ltd, and funded by AstraZeneca. AstraZeneca had no input into the study design, analysis, or interpretation of the results. |
| This observational study was funded by AstraZeneca Latin America. Editorial support was provided by Dr Ian Wright, Wright Medical Communications Ltd, and funded by AstraZeneca. AstraZeneca had no input into the study design, analysis, or interpretation of the results. |